Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
  • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
  • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7016—Disaccharides, e.g. lactose, lactulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
  • C12Y304/24—Metalloendopeptidases (3.4.24)
  • C12Y304/24003—Microbial collagenase (3.4.24.3)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
  • C12Y304/24—Metalloendopeptidases (3.4.24)
  • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1

Definitions

• XIAFLEX® (collagenase from Clostridium histolyticum (CCH)) is currently approved for the treatment of Dupuytren's Contracture (DC) and Peyronie's Disease (PD).
• DC Dupuytren's Contracture
• PD Peyronie's Disease
• the currently approved XIAFLEX® formulation is supplied as a lyophilized cake containing 0.9 mg CCH in 3CC vials along with a diluent vial.
• the current XIAFLEX® formulation pre- lyophilization
• has a lyophilization cycle time of about 72 hours in vials. Efficient lyophilization is required for shelf life and enzyme stability.
• formulations comprising: a collagenase; about 30 mM to about 240 mM of a disaccharide; about 50 mM to about 800 mM of mannitol; and about 6 mM to about 10 mM of a Tris-HCl.
• lyophilized formulations comprising: a collagenase; a disaccharide; mannitol; and Tris-HCl.
• kits comprising: a container comprising any of the disclosed lyophilized formulations; and a container comprising a sterile diluent comprising calcium chloride and sodium chloride.
• FIG 1 illustrates the effect of pH on protein interactions in exemplary formulations comprising trehalose, mannitol, and various collagenases.
• FIG. 2A and FIG. 2B illustrate an exemplary hydrogen peroxide challenges analyzing the effect of pH and excipients on turbidity.
• NTU - Nephelometric Turbidity Units NTU - Nephelometric Turbidity Units
• PS - Polysorbate T - Trehalose, S - Sucrose, M - Mannitol; H2O2 - Hydrogen peroxide; 7.5, 8.0, and 8.5 refers to formulation pH.
• 3R illustrate scanning electron microscopy (SEM) images of cakes from various lyophilized formulations (Va: 0.93 mg/ml CCH; 60 mM Sucrose; 112.5 mM Mannitol; 10 mM Tris/HCl buffer pH 8.5; Vb: 0.93 mg/ml CCH; 60 mM Sucrose; 225 mM Mannitol; 10 mM Tris/HCl buffer pH 8.5; and Vc: 0.93 mg/ml CCH; 60 mM Sucrose; 337.5 mM Mannitol; 10 mM Tris/HCl buffer pH 8.5).
• SEM scanning electron microscopy
• FIG. 4A, FIG. 4B, and FIG. 4C illustrate images of cakes from various lyophilized formulations under a pressure of 128 mbar (FIG. 4 A), 380 mbar (FIG. 4B), and 1030 pbar (FIG. 4C).
• FIG. 5A and FIG. 5B illustrate images of cakes from various lyophilized formulations under a pressure of 128 mbar (FIG. 5A) and 4000 mbar (FIG. 5B).
• FIG. 6 illustrates the moisture content over time in various lyophilized formulations.
• any description as to a possible mechanism or mode of action or reason for improvement is meant to be illustrative only, and the disclosed formulations are not to be constrained by the correctness or incorrectness of any such suggested mechanism or mode of action or reason for improvement.
• CH collagenase Clostridium histolyticum
• USP United States Pharmacopeia
• NTU Nephelometric Turbidity Units
• PS Polysorbate
• H2O2 Hydrogen peroxide
• formulations comprising, or consisting of:
• the formulations can contain between about 0.2 mg/ml to about 50 mg/ml of collagenase.
• the lyophilized formulation can contain about 0.2 mg/ml, about 0.3 mg/ml, about 0.4 mg/ml, about 0.6 mg/ml, about 0.8 mg/ml, about 0.9 mg/ml, about 1 mg/ml, about 1.2 mg/ml, about 1.4 mg/ml, about 1.6 mg/ml, about 1.8 mg/ml, about 2 mg/ml, about 2.5 mg/ml, about 3 mg/ml, about 3.5 mg/ml, about 4 mg/ml, about 4.5 mg/ml, about 5 mg/ml, about 10 mg/ml, about 15 mg/ml, about 20 mg/ml, about 25 mg/ml, about 30 mg/ml, about 35 mg/ml, about 40 mg/ml, about 45 mg/ml, or about 50 mg/ml of collagenase.
• collagenase from Vibrio alginolyticus (o) collagenase from Vibrio alginolyticus ; (p) collagenase from Streptomyces; (q) collagenase from Pseudomonas ; (r) collagenase from Achromobacter iophagus ; (s) collagenase described by Worthington Biochemical Corp. (www.Worthington-biochem.com;“Product Highlights”); (t) collagenase described by Sigma-Aldrich (www.sigma-aldrich.com); (u) collagenase having one or more of the following characteristics:
• the collagenase can comprise a collagenase I.
• a suitable collagenase I includes, for example, a collagenase I comprising an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1.
• the collagenase I comprises the amino acid sequence of SEQ ID NO: 1.
• the collagenase can comprise a collagenase II.
• a suitable collagenase II includes, for example, a collagenase II comprising an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 2.
• the collagenase II comprises the amino acid sequence of SEQ ID NO: 2.
• the collagenase can comprise a mixture of collagenase I and collagenase II.
• the collagenase can comprise, for example, a mixture of a collagenase I comprising an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1 and a collagenase II comprising an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 2.
• the collagenase comprises a mixture of the collagenase I comprising the amino acid sequence of SEQ ID NO: 1 and the collagenase II comprising the amino acid sequence of SEQ ID NO: 2.
• Suitable mixtures of the collagenase I and collagenase II include, for example, a collagenase Ecollagenase II mass ratio of 0.1 : 1, 0.25: 1, 0.5: 1, 0.75: 1, 1 : 1, 1.1 : 1, 1.25: 1, 1.5:1, 1.75: 1, 2: 1, 1 :0.1, 1 :0.25, 1 :0.5; 1 :0.75, 1 : 1.1, 1 : 1.25, 1 : 1.5, 1 : 1.75, or 1 :2.
• Each of the collagenase I and collagenase II may have a purity of at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% as measured by, for example, reverse phase HPLC.
• the collagenase can comprise collagenase Clostridium histolyticum (CCH).
• CH collagenase Clostridium histolyticum
• CCH histolyticum containing a mixture of collagenase I (SEQ ID NO: 1) and collagenase II (SEQ ID NO: 2) in an approximate 1 : 1 mass ratio.
• CCH is obtained by the fermentation of Clostridium histolyticum (also known as Hathewaya histolytica).
• Suitable disaccharides include those that:
• the disaccharide comprises sucrose or trehalose.
• the formulation comprises: a collagenase; about 30 mM to about 240 mM sucrose; about 50 mM to about 800 mM of mannitol; and about 6 mM to about 10 mM of a Tris-HCl.
• the formulation comprises: a collagenase; about 30 mM to about 240 mM of trehalose; about 50 mM to about 800 mM of mannitol; and about 6 mM to about 10 mM of a Tris-HCl.
• the disaccharide can be present at a concentration of about 30 mM to about 240 mM, about 60 mM to about 240 mM, about 90 mM to about 240 mM, about 120 mM to about 240 mM, about 150 mM to about 240 mM, about 180 mM to about 240 mM, about 210 mM to about 240 mM, about 30 mM to about 210 mM, about 30 mM to about 180 mM, about 30 mM to about 150 mM, about 30 mM to about 120 mM, about 30 mM to about 90 mM, or about 30 mM to about 60 mM.
• the disaccharide can be present at a concentration of about 30 mM, 60 mM, 90 mM, 120 mM, 150 mM, 180 mM, 210 mM, or 240 mM.
• the mannitol can be present at a concentration of about 50 mM to about 800 mM, about 100 mM to about 800 mM, about 150 mM to about 800 mM, about 200 mM to about 800 mM, about 250 mM to about 800 mM, about 300 mM to about 800 mM, about 350 mM to about 800 mM, about 400 mM to about 800 mM, about 450 mM to about 800 mM, about 500 mM to about 800 mM, about 550 mM to about 800 mM, about 600 mM to about 800 mM, about 650 mM to about 800 mM, about 700 mM to about 800 mM, about 750 mM to about 800 mM, about 50 mM to about 750 mM, about 50 mM to about 700 mM, about 50 mM to about 650 mM, about 50 mM to about 600 mM, about 50 mM to
• the mannitol can be present at a concentration of about 50 mM, 100 mM, 150 mM, 200 mM, 225 mM, 250 mM, 300 mM, 350 mM, 400 mM, 450 mM, 500 mM, 550 mM, 600 mM, 650 mM, 700 mM, 750 mM, or 800 mM.
• the pH of the formulation can be about 7.8 to about 8.8.
• the pH can be about 7.8, about 7.9, about 8.0, about 8.1, about 8.2, about 8.3, about 8.4, about 8.5, about 8.6, about 8.7, or about 8.8.
• the formulation can comprise: CCH; about 60 mM sucrose; about 225 mM mannitol; and about 10 mM Tris-HCl, wherein the formulation has a pH of about 8.5.
• the formulation can comprise: about 0.9 mg CCH/ml; about 60 mM sucrose; about 225 mM mannitol; and about 10 mM Tris-HCl, wherein the formulation has a pH of about 8.5.
• the formulation can consist of: CCH; about 60 mM sucrose; about 225 mM mannitol; and about 10 mM Tris-HCl, wherein the formulation has a pH of about 8.5.
• the formulation can consist of: about 0.9 mg CCH/ml; about 60 mM sucrose; about 225 mM mannitol; and about 10 mM Tris-HCl, wherein the formulation has a pH of about 8.5.
• the disclosed formulation can further comprise a surfactant.
• Suitable surfactants include, for example, polysorbate 20, polysorbate 80, or poloxamer 188.
• the surfactant can be present at a concentration of about 0.01% to about 2%, about 0.05% to about 2%, about 0.1% to about 2%, about 0.15% to about 2%, about 0.2% to about 2%, about 0.25% to about 2%, about 0.3% to about 2%, about 0.4% to about 2%, about 0.5% to about 2%, about 1% to about 2%, about 1.5% to about 2%, about 0.01% to about 1.5%, about 0.01% to about 1%, about 0.01% to about 0.5%, about 0.01% to about 0.1%, or about 0.01% to about 0.05%.
• the surfactant can be present at a concentration of about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.1%, 0.2%, 0.5%, 1%, 1.5%, or 2%.
• the formulation further comprises polysorbate 20 at a concentration of about 0.02%.
• the formulation further comprises polysorbate 80 at a concentration of about 0.02%.
• the formulation further comprises poloxamer 80 at a concentration of about 0.02%.
• the above formulations can be liquid.
• the disclosed formulations can be lyophilized under more aggressive conditions compared to previous collagenase-containing formulations, such as XIAFLEX®.
• the disclosed formulations can be lyophilized in shorter times, using higher pressures, and/or with fewer drying steps (e.g., single temperature drying), resulting in a lyophilized formulation that exhibits increased stability and that maintains acceptable collagenase activity upon reconstitution.
• the pH and mannitol lead to the formation of a more robust formulation that can subsequently undergo more aggressive lyophilization.
• lyophilized formulations can be formed by the lyophilization of any of the above formulations.
• the lyophilized formulations comprise, or consist of:
• the lyophilized formulation can contain between about 0.2 mg to about 50 mg of collagenase.
• the lyophilized formulation can contain about 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 0.9 mg, 1 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg,
• the collagenase can comprises a collagenase I.
• a suitable collagenase I includes, for example, a collagenase I comprising an amino acid sequence that is 90%, 91%,
• the collagenase I comprises the amino acid sequence of SEQ ID NO: 1.
• the collagenase can comprise a collagenase II.
• a suitable collagenase II includes, for example, a collagenase II comprising an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 2.
• the collagenase II comprises the amino acid sequence of SEQ ID NO: 2.
• the collagenase can comprise a mixture of collagenase I and collagenase II.
• the collagenase can comprise, for example, a mixture of a collagenase I comprising an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1 and a collagenase II comprising an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 2.
• the collagenase comprises a mixture of the collagenase I comprising the amino acid sequence of SEQ ID NO: 1 and the collagenase II comprising the amino acid sequence of SEQ ID NO: 2.
• Suitable mixtures of the collagenase I and collagenase II include, for example, a collagenase Tcollagenase II mass ratio of 0.1 : 1, 0.25: 1, 0.5: 1, 0.75: 1, 1 : 1, 1.1 : 1, 1.25: 1, 1.5: 1, 1.75: 1, 2: 1, 1 :0.1, 1 :0.25, 1 :0.5; 1 :0.75,
• the collagenase is
• Each of the collagenase I and collagenase II may have a purity of at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% as measured by, for example, reverse phase HPLC.
• Suitable disaccharides include, for example, sucrose or trehalose.
• the lyophilized formulation comprises, or consists of, a collagenase, sucrose, mannitol, and Tris-HCl.
• the lyophilized formulation comprises, or consists of, a collagenase, trehalose, mannitol, and Tris-HCl.
• the lyophilized formulations can be in a unit-dose vial, multi-dose vial, cartridge, or syringe.
• the lyophilized formulation can contain between about 0.2 mg to about 50 mg of collagenase.
• the lyophilized formulation can contain about 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 0.9 mg, 1 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, or 50 mg of collagenase.
• the vial, cartridge, or syringe can have a volume of 2 mL to 50 mL, such as 5 mL, 7.5 mL, 10 mL, 15 mL, 20 mL, 30 mL, 40 mL, or 50 mL.
• the vial, cartridge, or syringe can contain between about 0.2 mg to about 50 mg of collagenase.
• the vial, cartridge, or syringe can contain about 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg,
• the vial, cartridge, or syringe can contain between about 0.2 mg to about 50 mg of the lyophilized formulation.
• the vial, cartridge, or syringe can contain about 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg,
• the formulation Prior to lyophilization, can comprise, or consist of: a
• the formulation can comprise, or consist of: about 0.9 mg collagenase/ml;; about 30 mM to about 240 mM of a disaccharide; about 50 mM to about 800 mM of mannitol; and about 6 mM to about 10 mM of a Tris-HCl.
• the formulation Prior to lyophilization, can comprise, or consist of: CCH; 60 mM sucrose; 225 mM mannitol; 10 mM Tris-HCl, and have a pH of about 8.5.
• the formulation prior to lyophilization, can comprise, or consist of: about 0.9 mg CCH/ml; 60 mM sucrose; 225 mM mannitol; 10 mM Tris-HCl, and have a pH of about 8.5.
• the disclosed lyophilized formulations have increased stability compared to previous collagenase-containing formulations, such as XIAFLEX®.
• the disclosed lyophilized formulations are stable at pressures above 380 mbar , above 400 mbar, above 450 pbar, above 500 mbar, above 550 mbar , above 600 mbar, above 650 mbar, above 700 mbar, above 750mbar , above 800 mbar, above 850 mbar, above 900 mbar, above 950 mbar, above 1000 mbar, above 1500 mbar , above 2000 mbar, above 2500 mbar , above 3000 mbar, above 3500 mbar , or above 4000 mbar .
• the lyophilized formulation is stable at a pressure of about 4000 mbar .
• the disclosed lyophilized formulations also exhibit improved shelf life and storage conditions compared to previous collagenase-containing formulations.
• the disclosed lyophilized formulations exhibit an extended shelf life at low temperatures, such as 2- 8°C, and at elevated temperatures, such as room temperature (40°C / 75% relative humidity).
• the disclosed lyophilized formulation can be stable at, for example:
• the disclosed lyophilized formulation can be formed by a method comprising: freezing the formulation at a temperature between about -25°C and -55°C to form a frozen formulation; and drying the frozen formulation at a temperature between about 25°C and about 50°C to form the lyophilized formulation.
• Suitable temperatures for the freezing step include about -25°C , -30°C , -35°C , -40°C , -45°C, -50°C, or -55°C.
• Suitable temperatures for the drying step include about 25°C, 30°C, 35°C, 40°C, 45°C, or 50°C.
• the lyophilized formulations can be formed using a single temperature freezing step and a single temperature drying step.
• the lyophilized formulation can be formed by a method comprising: freezing the formulation at a single temperature between about -25°C and -55°C to form a frozen formulation; and drying the frozen formulation at a single temperature between about 25°C and about 50°C to form the lyophilized formulation.
• the single temperature freezing step can be performed at a temperature between about -25°C and about -55°C.
• the single temperature freezing step can be performed at about -25°C, -30°C, -35°C, -40°C -45°C, -50°C, or -55°C.
• the single temperature drying step can be performed at a temperature between about 25°C and about 50°C.
• the single temperature drying step can be performed at about 25°C, 30°C, 35°C, 40°C, 45°C, or 50°C.
• the method may further comprise a“ramp up” step between the freezing and drying to allow the lyophilizer to reach the suitable drying temperature.
• the disclosed lyophilized formulations can be formed by a lyophilization method that is much faster than the lyophilization method used to form other collagenase- containing lyophilized formulations.
• the lyophilized formulation can be formed by a
• lyophilization method that is performed for less than 72 hours. In some embodiments, the methods can be performed for less than 30 hours. In some embodiments, the methods can be performed for less than 18 hours. In some embodiments, the method can be performed for about 15 hours to about 25 hours.
• the disclosed lyophilized formulations can be formed by a lyophilization method that uses a much higher pressure than the lyophilization method used to form other collagenase-containing lyophilized formulations.
• the lyophilized formulation can be formed by a lyophilization method that is performed at a pressure of between about 380 mbar to about 4000 pbar.
• the disclosed methods can be performed at a pressure of between about 500 mbar to about 4000mbar , between about 750 mbar to about 4000 mbar , between about 1000 mbar to about 4000 pbar.
• the disclosed methods can be performed at 380 mbar, 500 mbar , 750 mbar, 1000 mbar,
• the disclosed lyophilized formulations once reconstituted, can be used to treat or reduce collagen-mediated conditions, including the severity of cellulite (also known as edematous fibrosclerotic panniculopathy (EFP)), Dupuytren's contracture (DC) with a palpable cord, or Peyronie's disease (PD) with a palpable plaque and curvature deformity of at least 30 degrees.
• EFP edematous fibrosclerotic panniculopathy
• DC Dupuytren's contracture
• PD Peyronie's disease
• the collagenase can comprise a collagenase I.
• a suitable collagenase I includes, for example, a collagenase I comprising an amino acid sequence that is 90%, 91%,
• the collagenase I comprises the amino acid sequence of SEQ ID NO: 1.
• the collagenase can comprise a collagenase II.
• a suitable collagenase II includes, for example, a collagenase II comprising an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 2.
• the collagenase II comprises the amino acid sequence of SEQ ID NO: 2.
• the collagenase can comprise a mixture of collagenase I and collagenase II.
• the collagenase can comprise, for example, a mixture of a collagenase I comprising an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1 and a collagenase II comprising an amino acid sequence that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 2.
• the collagenase comprises a mixture of the collagenase I comprising the amino acid sequence of SEQ ID NO: 1 and the collagenase II comprising the amino acid sequence of SEQ ID NO: 2.
• Suitable mixtures of the collagenase I and collagenase II include, for example, a collagenase Tcollagenase II mass ratio of 0.1 :1, 0.25: 1, 0.5: 1, 0.75: 1, 1 :1, 1.1 : 1, 1.25: 1, 1.5: 1, 1.75: 1, 2: 1, 1 :0.1, 1 :0.25, 1 :0.5; 1 :0.75,
• the collagenase is
• Each of the collagenase I and collagenase II may have a purity of at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% as measured by, for example, reverse phase HPLC.
• Suitable disaccharides include, for example, sucrose or trehalose.
• the reconstituted formulation comprises, or consists of, a collagenase, sucrose, mannitol, Tris-HCl, calcium chloride, and sodium chloride.
• the lyophilized formulation comprises, or consists of, a collagenase, trehalose, mannitol, Tris-HCl, calcium chloride, and sodium chloride.
• Suitable amounts of calcium chloride and sodium chloride include those that enable the reconstituted formulation to be isotonic to human blood.
• the reconstituted formulation comprises about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, or greater than 0.1% of calcium chloride.
• the reconstituted formulation comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, or greater than 1% of sodium chloride.
• the reconstituted formulation can also comprise water for injection (WFI).
• WFI water for injection
• the disclosed reconstituted formulations can be used to treat or reduce collagen- mediated conditions, including the severity of cellulite (also known as edematous fibrosclerotic panniculopathy (EFP)), Dupuytren's contracture (DC) with a palpable cord, or Peyronie's disease (PD) with a palpable plaque and curvature deformity of at least 30 degrees.
• EFP edematous fibrosclerotic panniculopathy
• DC Dupuytren's contracture
• PD Peyronie's disease
• the reconstituted formulations can comprise about 0.01 mg to about 50 mg of the collagenase in a single or divided dose.
• the reconstituted formulation can comprise, for example, about 0.05 mg to about 15 mg, about 0.10 mg to about 10 mg, about 0.15 mg to about 5 mg, about 0.20 mg to about 3 mg, or about 0.25 mg to about 2 mg of the collagenase in a single or divided dose.
• the reconstituted formulation can comprise, for example, about 0.05 mg, about 0.10 mg, about 0.15 mg, about 0.20 mg, about 0.25 mg, about 0.30 mg, about 0.35 mg, about 0.40 mg, about 0.45 mg, about 0.50 mg, about 0.55 mg, about 0.60 mg, about 0.65 mg, about 0.70 mg, about 0.75 mg, about 0.80 mg, about 0.85 mg, about 0.90 mg, about 0.95 mg, about 1.00 mg, 1.05 mg, about 1.10 mg, about 1.15 mg, about 1.20 mg, about 1.25 mg, about 1.30 mg, about 1.35 mg, about 1.40 mg, about 1.45 mg, about 1.50 mg, about 1.55 mg, about 1.60 mg, about 1.65 mg, about 1.70 mg, about 1.75 mg, about 1.80 mg, about 1.85 mg, about 1.90 mg, about 1.95 mg, about 2.00 mg, 2.05 mg, about 2.10 mg, about 2.15 mg, about 2.20 mg, about 2.25 mg, about 0.30 mg, about 2.35 mg, about 0.40 mg, about 0.45 mg,
• the reconstituted formulation can have a total volume of about 0.1 mL to about 50 mL.
• the reconstituted formulation can have a total volume of about 0.1 mL, 0.2 mL, 0.3 mL, 0.4 mL, 0.5 mL, 1 mL, 1.5 mL, 2 mL, 2.5 mL, 3 mL, 3.5 mL, 4 mL, 4.5 mL, 5 mL, 10 mL, 15 mL, 20 mL, 25 mL, 30 mL, 35 mL, 40 mL, 45 mL, or 50 mL.
• Kits comprising the disclosed lyophilized formulations and a sterile diluent are also provided.
• the kits can comprise: a container comprising any of the disclosed lyophilized formulations; and a container comprising a sterile diluent comprising calcium chloride and sodium chloride.
• Suitable containers for the lyophilized formulation and/or the sterile diluent include, for example, a vial, cartridge, or syringe.
• the vial can be a unit-dose vial or a multi dose vial.
• Suitable container sizes include, for example, 2 mL to 50 mL containers, such as 5 mL, 7.5 mL, 10 mL, 15 mL, 20 mL, 30 mL, 40 mL, or 50 mL.
• the container comprising the disclosed lyophilized formulation can comprise between about 0.2 mg to about 50 mg collagenase.
• the container can comprise about 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, or 50 mg collagenase.
• the container comprising the disclosed lyophilized formulation can comprise between about 0.2 mg to about 50 mg of the lyophilized formulation.
• the container can comprise about 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, or 50 mg of the lyophilized formulation.
• the container comprising the sterile diluent can comprise an amount of sterile diluent that, upon reconstitution of the lyophilized formulation, results in a solution that is isotonic to human blood.
• the sterile diluent comprises about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, or greater than 0.1% of calcium chloride.
• the sterile diluent comprises about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, or greater than 1% of sodium chloride.
• the volume of the sterile diluent can be about 0.1 mL to about 50 mL.
• the volume of the sterile diluent can be about 0.1 mL, 0.2 mL, 0.3 mL, 0.4 mL, 0.5 mL, 1 mL, 1.5 mL, 2 mL, 2.5 mL, 3 mL, 3.5 mL, 4 mL, 4.5 mL, 5 mL, 10 mL, 15 mL, 20 mL, 25 mL, 30 mL, 35 mL, 40 mL, 45 mL, or 50 mL.
• methods of lyophilizing any of the disclosed formulations comprising: freezing the formulation at a temperature between about -25°C and - 55°C to form a frozen formulation; and drying the frozen formulation at a temperature between about 25°C and about 50°C to form the lyophilized formulation.
• the freezing is performed at a single temperature and the drying is performed at a single temperature.
• the methods may further comprise a“ramp up” step between the freezing and drying to allow the lyophilizer to reach the suitable drying temperature.
• the single temperature freezing step can be performed at a temperature between about -25°C and about -55°C.
• the single temperature freezing step can be performed at about -25°C, -30°C, -35°C, -40°C, -45°C, -50°C, or -55°C.
• the single temperature drying step can be performed at a temperature between about 25°C and about 50°C.
• the single temperature drying step can be performed at about 25°C, 30°C, 35°C, 40°C, 45°C, or 50°C.
• the disclosed methods can be performed for less than 72 hours. In some embodiments, the methods can be performed for less than 30 hours. In some embodiments, the methods can be performed for less than 18 hours. In some embodiments, the method can be performed for about 15 hours to about 25 hours.
• the disclosed methods can be performed at a pressure of between about 128 pbar to about 4000 mbar, between about 380 mbar to about 4000 mbar, between about 500 mbar to about 4000 mbar , between about 750 mbar to about 4000 mbar , between about 1000 mbar to about 4000mbar .
• the disclosed methods can be performed at 380 mbar, 500 mbar , 750 mbar, 1000 pbar, 1500mbar , 2000 mbar, 2500 mbar, 3000 mbar , 3500 mbar, or 4000 mbar.
• the XIAFLEX® formulation (CCH, 10 mM Tris/HCl pH 8.0, 60 mM sucrose) has a relatively long lyophilization cycle time of 72 hours.
• An objective of the below studies was to achieve a more efficient lyophilization process with reduced cycle time and improved yields.
• pre-lyophilization As a part of the work to identify an optimal formulation composition for lyophilization, several different solution formulations (“pre-lyophilization”) containing various combinations of excipients such as sucrose, trehalose, and mannitol with and without surfactant at different levels were evaluated. In addition, untreated and siliconized (baked on) vials were also evaluated.
• VA Variant A: CCH, 10 mM Tris/HCl pH 8.5, 60 mM trehalose, 225 mM
• Variant B CCH, 10 mM Tris/HCl pH 8.0, 60 mM trehalose, 225 mM
• mannitol Original XIAFLEX® drug substance formulation (Or): CCH, 10 mM Tris/HCl pH 8.0,
• Standard glass vials and siliconized glass vials were used for the test to investigate the influence of hydrophobic surfaces on the protein stability.
• the formulations were supplemented with two types of surfactants (polysorbate 20 and poloxamer 188) to examine the influence of surfactants on the stability of the formulations during the challenge testing.
• a strong oxidizing agent hydrogen peroxide
• a matrix of 21 variants were used for the challenge testing.
• CCH was formulated in three different formulation variants.
• the formulation variants were exposed to thermal stress with agitation and freeze/thaw stress to challenge the formulation candidates. Hydrogen peroxide was added to the samples to force oxidative stress to the proteins. Each sample was analyzed after stress exposure by turbidity measurements to monitor the formation of aggregates.
• Vials were washed in a laboratory dishwasher with purified water. Afterwards, the vials were dried and heat-treated at 300°C for 2 hours for depyrogenization/sterilization. Stoppers were autoclaved at 2 bar and 121 °C for 20 min in sterilization bags and dried for 8 hours at 80°C.
• First XIAFLEX® drug substance was dialyzed against the formulation variants A or B. The dialysis was accomplished in three independent dialysis steps to achieve a quantitative buffer exchange. 60 ml of the XIAFLEX® drug substance was dialyzed against formulation variant A and 40 ml of the XIAFLEX® drug substance was dialyzed against formulation variant B. XIAFLEX® drug substance was transferred into two preconditioned (in dialysis buffer) Slide-A-LyzerTM cassettes (Thermo Scientific, Rockford, USA).
• Test samples of all formulations were stressed at 40°C for 4 days under agitation (200 rpm) in 2R vials (1 ml fill volume). Turbidity of the stressed samples was analyzed afterwards.
• the turbidity of the samples was determined using a 2100 AN turbidity meter (Hach Lange, Dusseldorf, Germany) according to the European Pharmacopeia. The system was calibrated as follows:
• Hydrazine sulphate solution Dissolved 1.0 g of hydrazine sulphate in purified water and diluted to 100.0 ml with the same solvent. Allowed to stand for 4-6 h.
• Hexamethylene tetramine solution Dissolved 2.5 g of hexamethylene tetramine in 25.0 ml purified water in a 100 ml glass-toppered volumetric flask.
• Reference suspensions Prepared the reference suspensions according to Table 3.
• Table 4 displays the result of the freeze/thaw testing. None of the variants showed an increase in turbidity with increasing number of freeze/thaw cycles. The enzymes seemed to be stable against freeze/thaw stress. The addition of surfactants or hydrogen peroxide showed no influence on the turbidity of the samples.
• Table 5 shows the results of the thermal stress at 40°C and agitation at 200 rpm. Variants containing hydrogen peroxide showed a clear increase of turbidity (as shown by the increased nephelometric turbidity units (NTU)) after thermal stress. In variants VA and variants VB (mannitol is present in both formulations) the resulting turbidity was remarkably lower (decreased NTU) than in the original XIAFLEX® formulation variant (“Or” - without mannitol). The beneficial effect of mannitol is believed to be caused by its radical scavenger properties.
• Collagenase I and collagenase II was dialyzed against the corresponding formulation buffer. After dialysis, the sample solutions were further diluted. Colloidal stability and thermodynamic stability of collagenase I, collagenase II, and the mixture was determined by CG-MALS and nanoDSC, respectively. The stability of the proteins in each formulation variant was additionally investigated in a stress test (freeze/thaw and thermal/shear stress) study. To force oxidative stress during the stability test, each formulation variant was examined in the presence and absence of 0.1 % H2O2 (sub-variant without hydrogen peroxide are marked with a; sub-variant with hydrogen peroxide are marked with b). Dialysis
• the dialysis of collagenase I and collagenase II was accomplished in three independent dialysis steps to achieve a quantitative buffer exchange. 14 ml of the collagenase I intermediate sample and 14 ml of the collagenase II intermediate sample was transferred into two preconditioned (in dialysis buffer) Slide-A-LyzerTM cassettes (Thermo Scientific, Rockford, USA). Filled Slide-A-LyzerTM cassettes were incubated in 1000 ml of the target buffer for 2 hours before a first buffer change (1000 ml) was performed. After dialysis for two further hours the buffer was changed a second time (1000 ml) to finalize the dialysis overnight. The protein sample was removed from the Slide-A-LyzerTM cassettes and processed further. Each dialysis step represents a 1/35 fold buffer exchange leading to a calculated buffer exchange factor of approx. 2 x 10 5 in total.
• DSC Differential Scanning Calorimetry
• Dialyzed samples were diluted with the corresponding formulation buffer to 1 mg/ml.
• the corresponding dialysis buffer was used as buffer scan and buffer reference.
• A2 is a measure of protein-protein interactions in solution.
• Negative Ai values indicate attractive protein-protein interactions while positive values indicate repulsive protein interactions.
• a protein solution is“colloidally unstable” when the Ai values are negative.
• a higher A2 value indicates greater repulsion, which is indicative of less protein interaction and less potential for protein aggregation and better stability.
• A2 values for various formulations were determined by CG-MALS and used as measures of non-specific protein- protein interactions
• the apparent weight average molecular weight (Mw app ) is determined for each step in the concentration gradient by analyzing the light scattering and concentration data.
• Mw Weight average molecular weight.
• Dialyzed samples were used undiluted for CG-MALS measurements.
• the corresponding dialysis buffer was used as diluent for the CG-MALS experiment.
• the samples and the buffer were passed over a 0.1 mm filter.
• concentration of the samples was determined by UV-absorption measurement. The concentration was used to calculate the concentrations of each gradient step.
• a Calypso II CG-MALS system was used to supply the MALS detector with the concentration gradient of the analyte.
• the samples were loaded on syringe pump 1 and syringe pump 2 of the system and the dialysis buffer on syringe pump 3.
• the CG-MALS measurement consisted of three steps. In the first step, a concentration gradient of sample 1 ranging from 10% to 100% was applied to determine the self-virial coefficient of sample 1 in the formulation.
• the second step consisted of a cross-over gradient, in which the concentration of sample 1 was reduced from 90% to 10% while the concentration of sample 2 was increased from 10% to 90%. This step was conducted to determine the cross-virial coefficient.
• a concentration gradient of sample 1 ranging from 10% to 100% was applied to determine the self-virial coefficient of sample 1 in the formulation.
• the second step consisted of a cross-over gradient, in which the concentration of sample 1 was reduced from 90% to 10% while the concentration of sample 2 was increased from 10% to 90%. This step was conducted to
• concentration gradient of sample 2 ranging from 100% to 10% was applied to determine the self- virial coefficient of sample 2 in the formulation.
• concentration gradient of sample 2 ranging from 100% to 10% was applied to determine the self- virial coefficient of sample 2 in the formulation.
• 0.7 ml of sample was injected into the MALS detector.
• the resulted light scattering signal was recorded over a time period of 180 sec.
• Multi component Zimm plot analysis with fixed molecular weight was performed with Calypso software version 2.1.5.
• the concentration of collagenase I and collagenase II in solution was determined using an 8452A UV spectrometer (Agilent Technologies, Santa Clara, USA).
• Samples were measured at a concentration of about 3 mg/ml using plastic cuvettes with an optical path thickness of 0.2 cm.
• the concentration was calculated according to Lambert-Beer's law using an extinction coefficient of 1.52 ml/(mg*cm) for collagenase I and 1 .48 ml/(mg*cm) for collagenase II, respectively.
• Dialyzed collagenase I and dialyzed collagenase II was mixed to exhibit a solution containing 0.5 mg/ml collagenase I and 0.5 mg/ml collagenase II.
• Test samples of all formulations were stressed at 40°C for 4 days under agitation (200 rpm) in 2R vials (1 ml fill volume). Turbidity of the stressed samples was analyzed afterwards.
• Table 7 shows the results of the CG-MALS and nanoDSC measurements of each formulation variant.
• thermodynamic stability - collagenase I showed a slight pH dependency of the onset temperature of unfolding. Higher T onset values were observed at pH 7.5 compared to pH 8.5. Mannitol showed slight and concentration dependent positive effect on the thermodynamic stability of collagenase I. The thermodynamic stability of collagenase II was independent from the investigated pH values. The presence of mannitol seemed to be beneficial for the thermodynamic stability of collagenase II.
• Table 8 shows the turbidity values of the samples during the subsequent freeze thaw cycles. .
• Table 9 shows the turbidity values of each formulation before and after thermal stress.
• CG-MALS Composition-Gradient Multi- Angle Light Scattering
• DSC Nano Differential Scanning Calorimetry
• Trehalose, sucrose, and mannitol also do not adversely affect the repulsive forces and are therefore were appropriate potential components of the formulation.
• Nano-DSC The variables studied using Nano-DSC to assess protein unfolding (pH, type and concentration of excipient) are presented in Table 16.
• Tonset onset temperature
• Tm protein melting temperature
• Lyophilization stoppers were autoclaved at 121°C for 15 min and dried for 8 hours at 105°C. Vials were rinsed with purified water and depyrogenized at 300°C for 2 hours.
• XIAFLEX® drug substance was accomplished in three independent dialysis steps to achieve a quantitative buffer exchange. 125 ml of the XIAFLEX® drug substance was dialyzed against variant a, b and c. XIAFLEX® drug substance was transferred into two preconditioned (in dialysis buffer) dialysis tubes. Filled dialysis tubes were incubated in 1 L of the target buffer for 2 hours before a first buffer change (1 L) was performed. After dialysis for two additional hours the buffer was changed a second time (2 L) to finalize the dialysis overnight. The protein sample was removed from the dialysis tube and the concentration was adjusted to 0.93 mg/ml ( ⁇ 10%) by dilution (concentration was checked by UV 280 nm). As a control, XIAFLEX® drug substance was used without dialysis.
• thermo couples were inserted into product vials. Pressure was controlled during lyophilization by using a Pirani- pressure sensor. Pressure regulation was managed via vacuum and dosing valve (nitrogen injection). Vials were closed at a pressure of 750 mbar under nitrogen atmosphere.
• the oven sample processor 774 enables a unique temperature ramping method in Karl Fischer titration.
• the sample was heated up by a defined heating rate and the released water was directly transferred into the titration chamber of the Karl-Fischer coulometer. By recording the generated water and the water drift (pg water /min) depending on the oven temperature, specified events where water was released (e.g. the release of hydrate water) can be detected.
• 50 to 100 mg of the lyophilizates was weighted into an empty 6R type 1 glass vial and closed with an alu-crimp-cab.
• the sample was transferred into the oven of the sample processor. There the sample is heated up by a defined temperature ramp from 50 °C to 140 °C in 45 min (2 °C/min). The ramp was concluded at 140 °C to exclude undesired Maillard-reactions.
• Lyophilizates were removed from the vial by carefully breaking the glass vial and the lyophilization cake was cut vertically to screen its inner layer for collapse zones.
• Lyophilizates were analyzed by SEM to evaluate their microstructure.
• Lyophilizates were cut, and the vertical cross sections and top/bottom surfaces were analyzed via SEM at 50x and 150x magnification.
• Vials were reconstituted with 4 ml of a solution containing 0.03% calcium chloride and 0.66% sodium chloride. Time for complete dissolution of the lyophilizates was recorded.
• Nano DSC was performed as described above.
• the primary drying step was terminated after about 17 hours of total lyophilization time. After 18 hours of secondary drying one vial of each variant was removed from the freeze dryer and the residual moisture level was determined by Karl-Fischer titration while the secondary drying step was prolonged for the rest of the batch. The Karl-Fischer analysis revealed that the residual moisture level was already below the desired value. Thus, the rest of the batch was unloaded immediately after receiving these results. Total duration of secondary drying was 19 hours.
• Residual moisture - Table 19 shows the residual moisture levels of the samples measured by Karl-Fischer titration.
• Nano DSC - Table 20 summarizes the obtained results.
• formulation #1 was buffer exchanged using dialysis to introduce the new excipients (trehalose, mannitol, and polysorbate 20) into the formulation in Tris buffer, pH 8.5.
• Experimental formulations #3 and #5 were selected for further testing. These formulations were used to conduct informal short term stability studies at 5°C and at accelerated storage conditions of 25°C / 60% RH. Samples were analyzed per approved test methods. All results generated for both formulations were in line with historical data for the XIAFLEX® formulation, indicating that the formulation changes being studied do not adversely affect product quality (data not shown). As noted previously, the currently approved limits may be revised based on a statistical analysis of data generated for the experimental formulations.
• FIG. 4A - FIG. 4C Pictures of the vials at the end of each pressure step are presented in FIG. 4A - FIG. 4C.
• the Control #1, XIAFLEX® in the vial shown on the far right
• the maximum tolerable pressure for the XIAFLEX® formulation was therefore between 128 mbar and 380 mbar, equivalent to an ice interface temperature of between -40°C and -30°C.
• Experimental Formulations #3 and #5 remained intact over the entire pressure range investigated.
• a second pressure test was conducted, in which experimental formulations #3 and #5 were further investigated.
• the pressure range was expanded to 4 mbar.
• the temperature of the shelf during the test was set to +10°C to provide sufficient energy input for enabling efficient sublimation at this pressure range.
• Run #1 Utilized experimental formulation #3 only. Results from this run indicated that a higher temperature during secondary drying is required to reach a residual moisture level below 0.5 %. Results for other physical attribute tests were acceptable (data not shown). A summary of the lyophilization parameters used are presented below:
• Run #2 Utilized experimental formulation #3 only. This run identified adequate conditions for drying using 40°C. All results were acceptable (data not shown). A summary of the lyophilization parameters used are presented below:
• Stability batches were tested for appearance (pre- and post-reconstitution), reconstitution time, osmolality, pH, concentration by UVA28O, quantitative sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), reverse-phase high performance liquid chromatography (RP-HPLC) [purity], mass and ratio by composition by RP-HPLC, size- exclusion high-performance liquid chromatography (SEC-HPLC), soluble rat tail collagen (SRC) assay for collagenase I potency, glycyl-L-prolyl-L-alanine (GPA) assay for collagenase II potency, moisture, particulates, endotoxin, and container closure integrity helium leak. Results and Analysis
• Container Closure Integrity /Helium Leak The results for container closure integrity /helium leak showed no significant changes or unexpected trends (data not shown).
• Available stability data for the 6 process validation lots of CCH formulation demonstrated stability of the material through at least the 18-month pull point at both 5°C and 25°C/60% RH storage conditions, as well as through the 6-month pull point at the 40°C/75% RH storage condition. Additionally, available data for a formulation development lot of the CCH formulation in a smaller vial demonstrated stability through the 24-month pull point at both the 5°C and 25°C/60% RH storage conditions as well as through the 6-month pull point at the 40°C/75% RH storage condition.
• CCH formulation Following reconstitution with sterile diluent, CCH formulation showed acceptable stability for up to 24 hours when stored at 25°C/60% RH and for up 120 hours when stored at 5°C. Reconstituted CCH formulation also demonstrated acceptable stability when stored at 25°C/60% RH for 24 hours, then at 2°C to 8°C for 96 hours and then at 25°C/60% RH for an additional 24 hours.
• Embodiment 1 A formulation comprising:
• Embodiment 2 The formulation of embodiment 1, wherein the collagenase comprises a collagenase I.
• Embodiment 3 The formulation of embodiment 2, wherein the collagenase I comprises the amino acid sequence of SEQ ID NO: 1.
• Embodiment 4 The formulation of embodiment 1, wherein the collagenase comprises a collagenase II.
• Embodiment 5 The formulation of embodiment 4, wherein the collagenase II comprises the amino acid sequence of SEQ ID NO: 2.
• Embodiment 6 The formulation of embodiment 1, wherein the collagenase comprises a mixture of collagenase I and collagenase II.
• Embodiment 7 The formulation of embodiment 6, wherein the collagenase I comprises the amino acid sequence of SEQ ID NO: 1 and the collagenase II comprises the amino acid sequence of SEQ ID NO: 2.
• Embodiment 8 The formulation of embodiment 6 or 7, wherein the collagenase is
• Embodiment 9 The formulation of any one of the previous embodiments, wherein the disaccharide comprises sucrose or trehalose.
• Embodiment 10 The formulation of any one of the previous embodiments, wherein the pH of the formulation is about 7.8 to about 8.8.
• Embodiment 11 The formulation of any one of the previous embodiments, wherein the formulation comprises:
• Embodiment 12 The formulation of any one of the previous embodiments, further comprising a surfactant comprising polysorbate 20, polysorbate 80, or poloxamer 188.
• Embodiment 13 The formulation of embodiment 12, comprising from about 0.01% to about 2% of the surfactant.
• Embodiment 14 The formulation of embodiment 13, comprising about 0.02% of the
• Embodiment 15 The formulation of any one of the previous embodiments, wherein the formulation is liquid.
• Embodiment 16 A lyophilized formulation comprising:
• Embodiment 17 The lyophilized formulation of embodiment 16, wherein the collagenase comprises a collagenase I.
• Embodiment 18 The lyophilized formulation of embodiment 17, wherein the collagenase I comprises the amino acid sequence of SEQ ID NO: 1.
• Embodiment 19 The lyophilized formulation of embodiment 16, wherein the collagenase comprises a collagenase II.
• Embodiment 20 The lyophilized formulation of embodiment 19, wherein the collagenase II comprises the amino acid sequence of SEQ ID NO: 2.
• Embodiment 21 The lyophilized formulation of embodiment 16, wherein the collagenase comprises a mixture of collagenase I and collagenase II.
• Embodiment 22 The lyophilized formulation of embodiment 21, wherein the collagenase I comprises the amino acid sequence of SEQ ID NO: 1 and the collagenase II comprises the amino acid sequence of SEQ ID NO: 2.
• Embodiment 23 The lyophilized formulation of embodiment 21 or 22, wherein the
• collagenase is collagenase Clostridium histolyticum (CCH).
• Embodiment 24 The lyophilized formulation of any one of embodiments 16-23, wherein the disaccharide comprises sucrose or trehalose.
• Embodiment 25 The lyophilized formulation of any one of embodiments 16-24, wherein, prior to lyophilization, the formulation comprises:
• Embodiment 26 The lyophilized formulation of any one of embodiments 16-25, wherein the lyophilized formulation is stable at pressures above 380 mba. r
• Embodiment 27 The lyophilized formulation of embodiment 26, wherein the lyophilized formulation is stable at a pressure of about 4000 mba.r
• Embodiment 28 The lyophilized formulation of any one of embodiments 16-27, wherein the lyophilized formulation is stable at:
• Embodiment 29 The lyophilized formulation of any one of embodiments 16-28, wherein the lyophilized formulation is formed by a method comprising:
• Embodiment 30 The lyophilized formulation of embodiment 29, wherein the lyophilized formulation is formed by a method comprising:
• Embodiment 31 The lyophilized formulation of any one of embodiments 16-30, wherein the lyophilized formulation is formed by a lyophilization method that is performed for less than 72 hours.
• Embodiment 32 The lyophilized formulation of any one of embodiments 16-31, wherein the lyophilized formulation is formed by a lyophilization method that is performed at a pressure of between about 380 mbar to about 4000 mba. r
• Embodiment 33 The lyophilized formulation of any one of embodiments 16-32, in a unit- dose vial, multi-dose vial, cartridge, or syringe.
• Embodiment 34 A reconstituted formulation comprising: a collagenase
• Embodiment 35 The reconstituted formulation of embodiment 34, wherein the collagenase is collagenase Clostridium histolyticum (CCH).
• CCH collagenase Clostridium histolyticum
• Embodiment 36 The reconstituted formulation of embodiment 34 or 35, wherein the
• disaccharide comprises sucrose or trehalose.
• Embodiment 37 The reconstituted formulation of any one of embodiments 34-36, wherein the reconstituted formulation is isotonic to human blood.
• Embodiment 38 A kit comprising:
• a container comprising the lyophilized formulation of any one of embodiments 16-32;
• a container comprising a sterile diluent comprising calcium chloride and sodium chloride.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• General Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Molecular Biology (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Dermatology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Enzymes And Modification Thereof (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=69845512

Family Applications (1)

Country Status (10)

Cited By (3)

Families Citing this family (2)

Citations (10)

Family Cites Families (3)

• 2020
  • 2020-01-03 US US17/419,899 patent/US20220305094A1/en not_active Abandoned
  • 2020-01-03 AU AU2020204922A patent/AU2020204922B2/en active Active
  • 2020-01-03 WO PCT/US2020/012202 patent/WO2020142701A1/en not_active Ceased
  • 2020-01-03 IL IL321891A patent/IL321891A/en unknown
  • 2020-01-03 BR BR112021012675-9A patent/BR112021012675A2/pt active Search and Examination
  • 2020-01-03 MX MX2021008017A patent/MX2021008017A/es unknown
  • 2020-01-03 KR KR1020217024557A patent/KR20210113271A/ko not_active Ceased
  • 2020-01-03 CN CN202080010875.3A patent/CN113382714A/zh active Pending
  • 2020-01-03 JP JP2021539410A patent/JP7565280B2/ja active Active
  • 2020-01-03 IL IL284270A patent/IL284270B2/en unknown
  • 2020-01-03 EP EP20712071.8A patent/EP3906014A1/en active Pending
• 2023
  • 2023-09-29 US US18/478,368 patent/US12303557B2/en active Active
• 2024
  • 2024-09-30 JP JP2024169863A patent/JP2025016453A/ja active Pending
• 2025
  • 2025-04-22 US US19/185,838 patent/US20250249080A1/en active Pending
  • 2025-06-30 AU AU2025204915A patent/AU2025204915A1/en active Pending

Patent Citations (10)

Also Published As

Similar Documents

Legal Events